RMTG launches ISSCA Peptide Certification 2.0 tied to Cellgenic products
The OTC-listed company says the physician training credential is company-issued and not a government or board-specialty accreditation.
The wire
- 01Regenerative Medical Technology Group said its ISSCA division expanded its peptide-medicine curriculum with updated modules and two new physician reference guides covering preparation, program design and clinical decision-making.
- 02The program is explicitly linked to subsidiary Cellgenic's peptide product portfolio, an education-to-product model clinicians should weigh when assessing the credential's independence.
- 03RMTG states the certification does not substitute for licensure, product labeling or regulatory authorization, and availability and clinical use remain subject to each jurisdiction's laws.
From the source
Read at newswire.comRMTG Expands Peptide Education Platform With ISSCA Peptide Certification 2.0 and New Physician Reference Guides
The upgraded program complements Cellgenic's expanding peptide training product portfolio and is intended as a current example of RMTG's education-to-product operating model.
